Mechanisms of sublingual immunotherapy

Journal of Asthma

Volumn 46, Issue 4, 2009, Pages 322-334

  Scadding, Guy ^a,b   Durham, Stephen ^a  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

^b ROYAL BROMPTON HOSPITAL   (United Kingdom)

Author keywords

Allergic rhinitis; Asthma; Immunotherapy; Mechanism; Sublingual

Indexed keywords

ALLERGEN; CD4 ANTIGEN; EOSINOPHIL CATIONIC PROTEIN; GAMMA INTERFERON; GRASS POLLEN EXTRACT; GRASS POLLEN VACCINE; HOUSE DUST ALLERGEN; IMMUNOGLOBULIN A; IMMUNOGLOBULIN E; IMMUNOGLOBULIN G; IMMUNOGLOBULIN G4; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 2 RECEPTOR ALPHA; INTERLEUKIN 4; INTERLEUKIN 5; MESSENGER RNA; TRANSCRIPTION FACTOR FOXP3; TRANSCRIPTION FACTOR GATA 3; TRANSFORMING GROWTH FACTOR BETA;

ALLERGIC ASTHMA; ALLERGIC RHINITIS; ANTIGEN PRESENTING CELL; CLINICAL TRIAL; CYTOKINE PRODUCTION; CYTOKINE RELEASE; DENDRITIC CELL; DRUG EFFICACY; DRUG MECHANISM; DRUG TOLERABILITY; EFFECTOR CELL; HAY FEVER; HOUSE DUST ALLERGY; HUMAN; IMMUNE RESPONSE; IMMUNOTHERAPY; NONHUMAN; ORAL ALLERGY SYNDROME; PERIPHERAL BLOOD MONONUCLEAR CELL; POLLEN ALLERGY; REVIEW; RHINOCONJUNCTIVITIS; SYNDROME; TH0 CELL; TH1 CELL; TH2 CELL; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT; ANIMAL; ASTHMA; COMPARATIVE STUDY; DESENSITIZATION; DISEASE MODEL; DOSE RESPONSE; DRUG EFFECT; FEMALE; IMMUNOLOGY; MALE; METHODOLOGY; MOUTH MUCOSA; PATIENT SATISFACTION; PERENNIAL RHINITIS; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; REGULATORY T LYMPHOCYTE; RHINITIS; RISK ASSESSMENT; SENSITIVITY AND SPECIFICITY; SUBCUTANEOUS DRUG ADMINISTRATION; SUBLINGUAL DRUG ADMINISTRATION; TREATMENT OUTCOME;

ADMINISTRATION, SUBLINGUAL; ANIMALS; ASTHMA; DESENSITIZATION, IMMUNOLOGIC; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; INJECTIONS, SUBCUTANEOUS; MALE; MOUTH MUCOSA; PATIENT SATISFACTION; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RHINITIS; RHINITIS, ALLERGIC, PERENNIAL; RHINITIS, ALLERGIC, SEASONAL; RISK ASSESSMENT; SENSITIVITY AND SPECIFICITY; T-LYMPHOCYTES, REGULATORY; TREATMENT OUTCOME;

EID: 67649756361     PISSN: 02770903     EISSN: 15324303     Source Type: Journal    
DOI: 10.1080/02770900902785729     Document Type: Review

References (77)

1. Durham SR, Walker SM, Varga EM, Jacobson MR, O'Brien F, Noble W, Till SJ, Hamid QA, Nouri-Aria KT. Long-term clinical efficacy of grass-pollen immunotherapy. N Engl J Med 1999; 341:468-475.
2. Golden DB, Kwiterovich KA, Kagey-Sobotka A, Valentine MD, Lichtenstein LM. Discontinuing venom immunotherapy: outcome after five years. J Allergy Clin Immunol 1996; 97:579-587.
3. Pajno GB, Barberio G, De Luca F, Morabito L, Parmiani S. Prevention of new sensitizations in asthmatic children monosensitized to house dust mite by specific immunotherapy. A six-year follow-up study. Clin Exp Allergy 2001; 31:1392-1397.
4. Möller C, Dreborg S, Ferdousi HA, Halken S, Høst A, Jacobsen L, Koivikko A, Koller DY, Niggemann B, Norberg LA, Urbanek R, Valovirta E, Wahn U. Pollen immunotherapy reduces the development of asthma in children with seasonal rhinoconjunctivitis (the PAT-study). J Allergy Clin Immunol 2002; 109:251-256.
5. Jacobsen L, Niggemann B, Dreborg S, Ferdousi HA, Halken S, Høst A, Koivikko A, Norberg LA, Valovirta E, Wahn U, Möller C; (The PAT investigator group). Specific immunotherapy has long-term preventive effect of seasonal and perennial asthma: 10-year follow-up on the PAT study. Allergy 2007; 62:943-948.
6. Wilson DR, Torres Lima M, Durham SR. Sublingual immunotherapy for allergic rhinitis: systematic review and meta-analysis. Allergy 2005; 60:4-12.
7. Calderon MA, Alves B, Jacobson M, Hurwitz B, Sheikh A, Durham S. Cochrane Database Syst Rev 2007; (1):CD001936.
8. Durham SR, Yang WH, Pederson MR, Johansen N, Rak S. Sublingual immunotherapy with once-daily grass allergen tablets: A randomized controlled trial in seasonal allergic rhinoconjunctivitis. J Allergy Clin Immunol 2006; 117:802-809.
9. Didier A, Malling HJ, Worm M, Horak F, Jäger S, Montagut A, André C, de Beaumont O, Melac M. Optimal dose, efficacy, and safety of once-daily sublingual immunotherapy with a 5-grass pollen tablet for seasonal allergic rhinitis. J Allergy Clin Immunol 2007; 120:1338-1345.
10. Dahl R, Kapp A, Colombo G, de Monchy JGR, Rak S, Emminger W, Riis B, Grønager PM, Durham SR. Sublingual grass allergen tablet im-munotherapy provides sustained clinical benefit with progressive immuno-logic changes over 2 years. J Allergy Clin Immunol 2008; 121:512-518.
11. Nouri-Aria KT, Wachholz PA, Francis JN, Jacobson MR, Walker SM, Wilcock LK, Staple SQ, Aalberse RC, Till SJ, Durham SR. Grass pollen im-munotherapy induces mucosal and peripheral IL-10 responses and blocking IgG activity. J Immunol 2004; 172:3252-3259.
12. Mothes N, Heinzkill M, Drachenberg KJ, Sperr WR, Krauth MT, Majlesi Y, Semper H, Valent P, Niederberger V, Kraft D, Valenta R. Allergen-specific immunotherapy with a monophosphoryl lipid A-adjuvanted vaccine: reduced seasonally boosted immunoglobulin E production and inhibition of basophil histamine release by therapy-induced blocking antibodies. Clin Exp Allergy 2003; 33:1198-1208.
13. Jutel M, Akdis M, Budak F, Aebischer-Casaulta C, Wrzyszcz M, Blaser K, Akdis CA. IL-10 and TGF-β cooperate in the regulatory T cell response to mucosal allergens in normal immunity and specific immunotherapy. Eur J Immunol 2003; 33:1205-1214.
14. Pilette C, Nouri-Aria KT, Jacobson MR, Wilcock LK, Detry B, Walker SM, Francis JN, Durham SR. Grass pollen immunotherapy induces an allergen-specific IgA2 antibody response associated with mucosal TGF-β expression. J Immunol 2007; 178:4658-4666.
15. Wachholz PA, Durham SR. Induction of 'blocking' IgG antibodies during immunotherapy. Clin Exp Allergy 2003; 33:1171-1174.
16. Shamji MH, Wilcock LK, Wachholz PA, Dearman RJ, Kimber I, Wurtzen PA, Larché M, Durham SR, Francis JN. The IgE-facilitated allergen binding (FAB) assay: validation of a novel flow-cytometric based method for the detection of inhibitory antibody responses. J Immunol Meth 2006; 317:71-79.
17. Daëron M, Malbec O, Latour S, Arock M, Fridman WH. Regulation of high-affinity IgE receptor-mediated mast cell activation by low-affinity IgG receptors. J Clin Invest 1995; 95:577-585.
18. Malbec O, Fong DC, Turner M, Tybulewicz VL, Cambier JC, Fridman WH, Daëron M. Fc epsilon receptor I-associated lyn-dependent phosphorylation of Fc gamma receptor IIB during negative regulation of mast cell activation. J Immunol 1998; 160:1647-1658.
19. Zhu D, Kepley CL, Zhang M, Zhang K, Saxon A. A novel human im-munoglobulin Fc-gamma- Fc-epsilon bifunctional fusion protein inhibits Fc-epsilon RI-mediated degranulation. Nat Med; 8:518-521.
20. Tam SW, Demissie S, Thomas D, Daëron M. A bispecific antibody against human IgE and human Fc- gamma RII that inhibits antigen-induced his-tamine release by human mast cells and basophils. Allergy 2004; 59:772-780.
21. Wilson DR, Irani AM, Walker SM, Jacobson MR, Mackay IS, Schwartz LB, Durham SR. Grass pollen immunotherapy inhibits seasonal increases in basophils and eosinophils in the nasal epithelium. Clin Exp Allergy 2001; 31:1705-1713.
22. Durham SR, Ying S, Varney VA, Jacobson MR, Sudderick RM, Mackay IS, Kay AB, Hamid QA. Grass pollen immunotherapy inhibits allergen-induced infiltration of CD4+ T lymphocytes and eosinophils in the nasal mucosa and increases the number of cells expressing messenger RNA for interferon-gamma. J Allergy Clin Immunol 1996; 97:1356-1365.
23. Ling EM, Smith T, Nguyen XD, Pridgeon C, Dallman M, Arbery J, Carr VA, Robinson DS. Relation of CD4+CD25+ regulatory T-cell suppression of allergen-driven T-cell activation to atopic status and expression of allergic disease. Lancet 2004; 363 (9409):608-615.
24. Robinson DS, Larché M, Durham SR. Tregs and allergic disease. J Clin Invest 2004; 114:1389-1397.
25. Francis JN, Till SJ, Durham SR. Induction of IL-10+CD4+CD25+ T cells by grass pollen immunotherapy. J Allergy Clin Immunol 2003; 111:1255-1261.
26. Ebner C, Siemann U, Bohle B, Willheim M, Wiedermann U, Schenk S, Klotz F, Ebner H, Kraft D, Scheiner O. Immunological changes during specific immunotherapy of grass pollen allergy: reduced lymphoprolifer-ative responses to allergen and shift from TH2 to TH1 in T-cell clones specific for Phl p 1, a major grass pollen allergen. Clin Exp Allergy 1997; 27:1007-1015.
27. Till S, Walker S, Dickason R, Huston D, O'Brien F, Lamb J, Kay AB, Corrigan C, Durham S. IL-5 production by allergen-stimulated T cells following grass pollen immunotherapy for seasonal allergic rhinitis. Clin Exp Immunol 1997; 110:114-121.
28. Wachholz PA, Nouri-Aria KT, Wilson DR, Walker SM, Verhoef A, Till SJ, Durham SR. Grass pollen immunotherapy for hayfever is associated with increases in local nasal but not peripheral Th1:Th2 cytokine ratios. Immunology 2002; 105:56-62.
29. Klimek L, Dormann D, Jarman ER, Cromwell O, Riechelmann H, Reske-Kunz AB. Short-term preseasonal birch pollen allergoid immunotherapy influences symptoms, specific nasal provocation and cytokine levels in nasal secretions, but not peripheral T-cell responses, in patients with allergic rhinitis. Clin Exp Allergy 1999; 29:1326-1335.
30. Radulovic S, Jacobson MR, Durham SR, Nouri-Aria KT. Grass pollen immunotherapy induces Foxp3-expressing CD4+ CD25+ cells in the nasal mucosa. J Allergy Clin Immunol 2008; 121:1467-1472.
31. Akdis CA, Joss A, Akdis M, Faith A, Blaser K. A molecular basis for T cell suppression by IL-10: CD28-associated IL-10 receptor inhibits CD28 tyrosine phosphorylation and phosphatidylinositol 3-kinase binding. FASEB J 2000; 14:1666-1668.
32. Jeannin P, Lecoanet S, Delneste Y, Gauchat JF, Bonnefoy JY. IgE versus IgG4 production can be differentially regulated by IL-10. J Immunol 1998; 160:3555-3561.
33. Bagnasco M, Mariani G, Passalacqua G, Motta C, Bartolomei M, Falagiani P, Mistrello G, Canonica GW. Absorption and distribution kinetics of the major Parietaria judaica allergen (Par j 1) administered by noninjectable routes in healthy human beings. J Allergy Clin Immunol 1997; 100:122-129.
34. Bagnasco M, Passalacqua G, Villa G, Augeri C, Flamigni G, Borini E, Falagiani P, Mistrello G, Canonica GW, Mariani G. Pharmacokinetics of an allergen and a monomeric allergoid for oromucosal immunotherapy in allergic volunteers. Clin Exp Allergy 2001; 31:54-60.
35. Razafindratsita A, Saint-Lu N, Mascarell L, Berjont N, Bardon T, Betbeder D, Van Overtvelt L, Moingeon P. Improvement of sublingual immunotherapy efficacy with a mucoadhesive allergen formulation. J Allergy Clin Immunol 2007; 120:278-285.
36. Allam JP, Novak N, Fuchs C, Asen S, Bergé S, Appel T, Geiger E, Kochan JP, Bieber T. Characterization of dendritic cells from human oral mucosa: a new Langerhans' cell type with high constitutive Fc-epsilon RI expression. J Allergy Clin Immunol 2003; 112:141-148.
37. Noirey N, Rougier N, André C, Schmitt D, Vincent C. Langerhans-like dendritic cells generated from cord blood progenitors internalize pollen allergens by macropinocytosis, and part of the molecules are processed and can activate autologous naive T lymphocytes. J Allergy Clin Immunol 2000; 105 (6 pt 1):1194-1201.
38. Allam JP, Stojanovski G, Friedrichs N, Peng W, Bieber T, Wenzel J, Novak N. Distribution of Langerhans cells and mast cells within the human oral mucosa: new application sites of allergens in sublingual immunotherapy? Allergy 2008; 63:720-727.
39. Zemann B, Schwaerzler C, Griot-Wenk M, Nefzger M, Mayer P, Schneider H, de Weck A, Carballido JM, Liehl E. Oral administration of specific antigens to allergy-prone infant dogs induces IL-10 and TGF- beta expression and prevents allergy in adult life. J Allergy Clin Immunol 2003; 111:1069-1075.
40. Akbari O, DeKruyff RH, Umetsu DT. Pulmonary dendritic cells producing IL-10 mediate tolerance induced by respiratory exposure to antigen. Nat Immunol 2001; 2:725-731.
41. Wakkach A, Fournier N, Brun V, Breittmayer JP, Cottrez F, Groux H. Characterization of dendritic cells that induce tolerance and T regulatory 1 cell differentiation in vivo. Immunity 2003; 18:605-617.
42. Van Wilsem EJ, Van Hoogstraten IM, Brevé J, Scheper RJ, Kraal G. Dendritic cells of the oral mucosa and the induction of oral tolerance. A local affair. Immunology 1994; 83:128-132.
43. Novak N, Bieber T, Katoh N. Engagement of Fc epsilon RI on human monocytes induces the productionofIL-10 and prevents their differentiation in dendritic cells. J Immunol 2001; 167:797-804.
44. von Bubnoff D, Matz H, Frahnert C, Rao ML, Hanau D, de la Salle H, Bieber T. Fc-epsilonRI induces the tryptophan degradation pathway involved in regulating T cell responses. J Immunol 2002; 169:1810-1816.
45. Allam JP, Peng WM, Appel T, Wenghoefer M, Niederhagen B, Bieber T, Bergé S, Novak N. Toll-like receptor 4 ligation enforces tolerogenic properties of oral mucosal Langerhans cells. J Allergy Clin Immunol 2008; 121:368-374.
46. Van Overtvelt L, Lombardi V, Razafindratsita A, Saint-Lu N, Horiot S, Moussu H, Mascarell L, Moingeon P. IL-10-inducing adjuvants enhance sublingual immunotherapy efficacy in a murine asthma model. Int Arch Allergy Immunol 2008; 145:152-162.
47. Brimnes J, Kildsgaard J, Jacobi H, Lund K. Sublingual immunotherapy reduces allergic symptoms in a mouse model of rhinitis. Clin Exp Allergy 2007; 37:488-497.
48. Petersen AB, Gudmann P, Milvang-Grønager P, Mørkeberg R, Bøgestrand S, Linneberg A, Johansen N. Performance evaluation of a specific IgE assay developed for the ADVIA centaur immunoassay system. Clin Biochem 2004; 37:882-892.
49. Radulovic S, Calderon M, Wilson S, Durham S. Sublingual immunother-apy for allergic rhinitis: an updated Cochrane systemic review and meta-analysis. Allergy 2007; 62(suppl 83):263.
50. Marcucci F, Sensi L, Di Cara G, Incorvaia C, Frati F. Dose dependence of immunological response to sublingual immunotherapy. Allergy 2005; 60:952-956.
51. Lima MT, Wilson D, Pitkin L, Roberts A, Nouri-Aria K, Jacobson M, Walker S, Durham S. Grass pollen sublingual immunotherapy for seasonal rhinoconjunctivitis: a randomized controlled trial. Clin Exp Allergy 2002; 32:507-514.
52. Rossi RE, Monasterolo G, Coco G, Silvestro L, Operti D. Evaluation of serum IgG4 antibodies specific to grass pollen allergen components in the follow up of allergic patients undergoing subcutaneous and sublingual immunotherapy. Vaccine 2007; 25:957-964.
53. André C, Perrin-Fayolle M, Grosclaude M, Couturier P, Basset D, Cornillon J, Piperno D, Girodet B, Sanchez R, Vallon C, Bellier P, Nasr M. A double-blind placebo-controlled evaluation of sublingual immunotherapy with a standardized ragweed extract in patients with seasonal rhinitis. Evidence for a dose-response relationship. Int Arch Allergy Immunol 2003; 131:111-118.
54. Bousquet J, Scheinmann P, Guinnepain MT, Perrin-Fayolle M, Sauvaget J, Tonnel AB, PauliG,CaillaudD,DubostR,LeynadierF,VervloetD,Herman D, Galvain S, André C. Sublingual-swallow immunotherapy (SLIT) in patients with asthma due to house-dust mites: a double-blind, placebo-controlled study. Allergy 1999; 54:249-260.
55. Lue KH, Lin YH, Sun HL, Lu KH, Hsieh JC, Chou MC. Clinical and immunologic effects of sublingual immunotherapy in asthmatic children sensitized to mites: a double-blind, randomized, placebo-controlled study. Pediatr Allergy Immunol 2006; 17:408-415.
56. Aberer W, Hawranek T, Reider N, Schuster C, Sturm G, Kränke BIm-munoglobulin E and G antibody profiles to grass pollen allergens during a short course of sublingual immunotherapy. J Investig Allergol Clin Immunol 2007; 17:131-136.
57. Rolinck-Werninghaus C, Kopp M, Liebke C, Lange J, Wahn U, Niggemann B. Lack of detectable alterations in immune responses during sublingual immunotherapy in children seasonal allergic rhinoconjunctivitis to grass pollen. Int Arch Allergy Immunol 2005; 136:134-141.
58. Pajno GB, Morabito L, Barberio G, Parmiani S. Clinical and immunologic effects of long-term sublingual immunotherapy in asthmatic children sensitized to mites: a double-blind, placebo-controlled study. Allergy 2000; 55:842-849.
59. Tonnel AB, Scherpereel A, Douay B, Mellin B, Leprince D, Goldstein N, Delecluse P, Andre C. Allergic rhinitis due to house dust mites: evaluation of the efficacy of specific sublingual immunotherapy. Allergy 2004; 59:491-497.
60. Bahceciler NN, Arikan C, Taylor A, Akdis M, Blaser K, Barlan IB, Akdis CA. Impact of sublingual immunotherapy on specific antibody levels in asthmatic children allergic to house dust mites. Int Arch Allergy Immunol 2005; 136:287-294.
61. Dehlink E, Eiwegger T, Gerstmayr M, Kampl E, Bohle B, Chen KW, Vrtala S, Urbanek R, Szépfalusi Z. Absence of systemic immunologic changes during dose build-up phase and early maintenance period in effective specific sublingual immunotherapy in children. Clin Exp Allergy 2006; 36:32-39.
62. Passalacqua G, Albano M, Fregonese L, Riccio A, Pronzato C, Mela GS, Canonica GW. Randomised controlled trial of local allergoid immunother-apy on allergic inflammation in mite-induced rhinoconjunctivitis. Lancet 1998; 351 (9103):629-632.
63. Passalacqua G, Albano M, Riccio A, Fregonese L, Puccinelli P, Parmiani S, Canonica GW. Clinical and immunologic effects of a rush sublingual immunotherapy to Parietaria species: A double-blind, placebo-controlled trial. J Allergy Clin Immunol 1999; 104:964-968.
64. Arikan C, Bahceciler NN, Deniz G, Akdis M, Akkoc T, Akdis CA, Barlan IB. Bacillus Calmette-Guérin-induced interleukin-12 did not additionally improve clinical and immunologic parameters in asthmatic children treated with sublingual immunotherapy. Clin Exp Allergy 2004; 34:398-405.
65. Ippoliti F, De Santis W, Volterrani A, Lenti L, Canitano N, Lucarelli S, Frediani T. Immunomodulation during sublingual therapy in allergic children. Pediatr Allergy Immunol 2003; 14:216-221.
66. Marcucci F, Sensi L, Frati F, Senna GE, Canonica GW, Parmiani S, Passalac-qua G. Sublingual tryptase and ECP in children treated with grass pollen sublingual immunotherapy (SLIT): safety and immunologic implications. Allergy 2001; 56:1091-1095.
67. Castells M, Schwartz LB. Tryptase levels in nasal-lavage fluid as an indicator of the immediate allergic response. J Allergy Clin Immunol 1988; 82(3 Pt 1):348-355.
68. Marcucci F, Sensi L, Incorvaia C, Di Cara G, Moingeon P, Frati F. Oral reactions to sublingual immunotherapy: a bioptic study. Allergy 2007; 62:1475-1477.
69. Bohle B, Kinaciyan T, Gerstmayr M, Radakovics A, Jahn-Schmid B, Ebner C. Sublingual immunotherapy induces IL-10-producing T regulatory cells, allergen-specific T-cell tolerance, and immune deviation. J Allergy Clin Immunol 2007; 120:707-713.
70. Fanta C, Bohle B, Hirt W, Siemann U, Horak F, Kraft D, Ebner H, Ebner C. Systemic immunological changes induced by administration of grass pollen allergens via the oral mucosa during sublingual immunotherapy. Int Arch Allergy Immunol 1999; 120:218-224.
71. Cosmi L, Santarlasci V, Angeli R, Liotta F, Maggi L, Frosali F, Rossi O, Falagiani P, Riva G, Romagnani S, Annunziato F, Maggi E. Sublingual immunotherapy with Dermatophagoides monomeric allergoid down-regulates allergen-specific immunoglobulinEand increases both interferon-gamma- and interleukin-10-production. Clin Exp Allergy 2006; 36:261-272.
72. Ciprandi G, Fenoglio D, Cirillo I, Vizzaccaro A, Ferrera A, Tosca MA, Puppo F. Induction of interleukin 10 by sublingual immunotherapy for house dust mites: a preliminary report. Ann Allergy Asthma Immunol 2005; 95:38-44.
73. Fenoglio D, Puppo F, Cirillo I, Vizzaccaro A, Ferrera A, Tosca MA, Marseglia G, Ciprandi G. Sublingual specific immunotherapy reduces PBMC proliferations. Eur Ann Allergy Clin Immunol 2005; 37:147-151.
74. Savolainen J, Jacobsen L, Valovirta E. Sublingual immunotherapy in children modulates allergen-induced in vitro expression of cytokine mRNA in PBMC. Allergy 2006; 61:1184-1190.
75. Savolainen J, Nieminen K, Laaksonen K, Laiho T, Jacobsen L, Lahesmaa R, Terho EO, Valovirta E. Allergen-induced in vitro expression of IL-18, SLAM and GATA-3 mRNA in PBMC during sublingual immunotherapy. Allergy 2007; 62:949-953.
76. Ciprandi G, Cirillo I, Fenoglio D, Marseglia G, Tosca MA. Sublingual immunotherapy induces spirometric improvement associated with IL-10 production: preliminary reports. Int Immunopharmacol 2006; 6:1370-1373.
77. Moingeon P, Batard T, Fadel R, Frati F, Sieber J, Van Overtvelt L. Immune mechanisms of allergen-specific sublingual immunotherapy. Allergy 2006; 61:151-165.